Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Revenue: 2016-2025

Historic Revenue for Seres Therapeutics (MCRB) over the last 8 years, with Sep 2025 value amounting to $351,000.

  • Seres Therapeutics' Revenue was N/A to $351,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $107,000, marking a year-over-year change of. This contributed to the annual value of $126.3 million for FY2023, which is 1672.24% up from last year.
  • As of Q3 2025, Seres Therapeutics' Revenue stood at $351,000, which was up 156.80% from -$618,000 recorded in Q1 2024.
  • Seres Therapeutics' 5-year Revenue high stood at $126.7 million for Q3 2021, and its period low was -$618,000 during Q1 2024.
  • Its 3-year average for Revenue is $21.2 million, with a median of $330,500 in 2023.
  • In the last 5 years, Seres Therapeutics' Revenue skyrocketed by 10,300.74% in 2023 and then tumbled by 218.39% in 2024.
  • Seres Therapeutics' Revenue (Quarterly) stood at $7.2 million in 2021, then slumped by 86.50% to $975,000 in 2022, then tumbled by 93.44% to $64,000 in 2023, then slumped by 218.39% to -$618,000 in 2024, then reached $351,000 in 2025.
  • Its last three reported values are $351,000 in Q3 2025, -$618,000 for Q1 2024, and $64,000 during Q4 2023.